Lv7
4775 积分 2020-03-31 加入
Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial
27天前
已完结
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
1个月前
已完结
ViPOR’s Venom — Rationally Targeting DLBCL with Precision
1个月前
已完结
A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
1个月前
已完结
Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma
1个月前
已关闭
The “purfling sign”: a new imaging marker for the diagnosis of primary CNS lymphoma
2个月前
已完结
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
3个月前
已完结
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
4个月前
已完结
Tirabrutinib: First Approval
4个月前
已完结
皖公网安备34019202002308
